Literature DB >> 33990906

Ischemia reperfusion injury induces pyroptosis and mediates injury in steatotic liver thorough Caspase 1 activation.

Vasantha L Kolachala1, Chrissy Lopez1, Ming Shen1, Dmitry Shayakhmetov1, Nitika Arora Gupta2,3.   

Abstract

A steatotic liver is increasingly vulnerable to ischemia reperfusion injury (IRI), and the underlying mechanisms are incompletely defined. Caspases are endo-proteases, which provide critical regulatory connections between cell death and inflammation. Caspase 1 is driven by inflammasomes which are key signaling platforms, that detect sterile stressors (DAMPs), releasing the highly pro-inflammatory cytokine interleukin IL-8 and IL-1β. To delineate the involvement of Caspase 1 and 11 in hepatocellular injury in steatotic liver undergoing IRI. Male C57BL6/Wild Type and Caspase 1Null, Caspase 11-/- and Caspase 1-/-/11-/- mice were fed a high fat diet (HFD) for 12 weeks. These mice were subjected to 40 min of ischemia followed by 2-24 h of reperfusion. Hepatocellular injury was assessed by histopathologic injury scoring, serum ALT and propidium iodide (PI) uptake, mRNA levels of Caspase 1, IL-1β by RT PCR, Caspase 1 activity assay and Caspase 1. Specific Caspase 1, inhibitor experiments were carried out. All groups gained similar body weight after a 12-week HFD. Cleaved Caspase 1 protein levels, Caspase 1 mRNA levels were significantly higher in steatotic liver undergoing IRI. Executor of pyroptosis cleaved GSDMD levels were higher in HFD fed mouse compared to lean. In addition, genetic deletion of Caspase 1, Casp1Null mouse expressing Caspase-11 and Caspase 1/11 double knock out demonstrated significant reduction in serum ALT (p < 0.01), Injury Score, (p < 0.0002) but not in Caspase 11 alone. Caspase 1 is the driver of hepatocellular injury in a steatotic liver undergoing IRI, inhibition of which leads to hepatoprotection, thus providing a therapeutic target for clinical use.

Entities:  

Keywords:  Caspase 1; Caspase 11; Ischemia reperfusion injury; Pyroptosis; Steatosis

Mesh:

Substances:

Year:  2021        PMID: 33990906     DOI: 10.1007/s10495-021-01673-1

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   5.561


  2 in total

1.  Involvement of ICE family proteases in apoptosis induced by reoxygenation of hypoxic hepatocytes.

Authors:  S Shimizu; Y Eguchi; W Kamiike; Y Akao; H Kosaka; J Hasegawa; H Matsuda; Y Tsujimoto
Journal:  Am J Physiol       Date:  1996-12

Review 2.  Non-alcoholic fatty liver disease: controlling an emerging epidemic, challenges, and future directions.

Authors:  Andrew Ofosu; Daryl Ramai; Madhavi Reddy
Journal:  Ann Gastroenterol       Date:  2018-02-23
  2 in total
  5 in total

1.  The role of MLKL in Hepatic Ischemia-Reperfusion Injury of Alcoholic Steatotic Livers.

Authors:  Hao Chen; Tara McKeen; Xiaojuan Chao; Allen Chen; Fengyan Deng; Hartmut Jaeschke; Wen-Xing Ding; Hong-Min Ni
Journal:  Int J Biol Sci       Date:  2022-01-01       Impact factor: 6.580

2.  STING Induces Liver Ischemia-Reperfusion Injury by Promoting Calcium-Dependent Caspase 1-GSDMD Processing in Macrophages.

Authors:  Xin-Yi Wu; Ya-Jun Chen; Chang-An Liu; Jun-Hua Gong; Xue-Song Xu
Journal:  Oxid Med Cell Longev       Date:  2022-01-30       Impact factor: 6.543

3.  Programmed cell death lives.

Authors:  Arjan W Griffioen; Patrycja Nowak-Sliwinska
Journal:  Apoptosis       Date:  2022-08-09       Impact factor: 5.561

4.  XueFu ZhuYu Decoction Alleviates Cardiopulmonary Bypass-Induced NLRP3 Inflammasome-Dependent Pyroptosis by Inhibiting IkB-α/NF-κB Pathway in Acute Lung Injury Rats.

Authors:  Hui Li; Wenlei Zhang; Qiaoqin Lou; Yuejin Chang; Zhenhao Lin; Lingli Lou
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-10       Impact factor: 2.650

Review 5.  Novel Targets and Therapeutic Strategies to Protect Against Hepatic Ischemia Reperfusion Injury.

Authors:  Xin-Li Mao; Yue Cai; Ya-Hong Chen; Yi Wang; Xiu-Xiu Jiang; Li-Ping Ye; Shao-Wei Li
Journal:  Front Med (Lausanne)       Date:  2022-01-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.